Poor
Not Aligned
Patient Risk:
Low
Summary
The claims evaluated are exclusively about Sohonos cost drivers/availability. The provided FDA label excerpts do not address pricing, insurance, pharmacy benefit, discounts, copays, patient assistance, or cost determinants, so the statements cannot be confirmed against the labeling.
Category Scores
Accurate Statements
Unsupported Statements
Sohonos (the brand name most often used for treatment of fibrodysplasia ossificans progressiva) is a prescription drug.
The supplied labeling excerpts do not state that Sohonos is a prescription drug or discuss this phrasing.
The cost of Sohonos depends on the patient’s country.
The provided FDA label excerpts do not contain any information about pricing by country or cost determinants.
The cost of Sohonos depends on insurance coverage.
The provided FDA label excerpts do not contain any information about how insurance affects price.
The cost of Sohonos depends on whether it is purchased through a pharmacy benefit.
The provided FDA label excerpts do not discuss pharmacy benefit pricing or reimbursement mechanisms.
The cost of Sohonos depends on the dosing regimen prescribed.
The provided FDA label excerpts do not provide pricing information or link cost to dosing regimen.
Sohonos prices vary based on negotiated discounts.
The provided FDA label excerpts do not address negotiated discounts.
Sohonos prices vary based on copays.
The provided FDA label excerpts do not discuss copays or patient out-of-pocket cost components.
Sohonos prices vary based on patient-assistance availability.
The provided FDA label excerpts do not discuss patient assistance programs or their impact on cost.
The exact cost of Sohonos cannot be stated reliably without details such as the patient’s country and insurance/payment method.
The provided FDA label excerpts do not include statements regarding the ability to state exact cost or required patient details.
Manufacturer discount programs may apply to Sohonos cash price/self-pay quotes.
The provided FDA label excerpts do not describe discount programs or apply-to-cash pricing language.
Insurance formulary copay/coinsurance and prior-authorization requirements can affect Sohonos price for a patient.
The provided FDA label excerpts do not discuss formulary placement, prior authorization, or how these factors affect price.
Contradictions
Important Omissions
No on-label efficacy, dosing, contraindications, warnings/precautions, adverse reactions, monitoring, drug interactions, or storage information was addressed in the AI claims provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern cost/coverage mechanics and do not conflict with the label excerpts provided; however, they are unsupported by the provided FDA labeling excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about pricing/cost determinants are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit evaluation to sections included in the supplied label excerpts (indications, contraindications, warnings/precautions, adverse reactions, pediatric use, etc.) and avoid making pricing/insurance/cost assertions unless the FDA label explicitly contains such information.